Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 25, 2026
CEVA vs MXL: Contrasting AI Semiconductor Paths After MXL's +400% Surge

CEVA vs MXL: Contrasting AI Semiconductor Paths After MXL's +400% Surge

Key Takeaways

  • Different semiconductor models: Ceva licenses intellectual property (IP) for wireless connectivity and edge AI, while MaxLinear sells physical radio-frequency and optical data-center chips.
  • Scale gap: MaxLinear's roughly $7.7 billion market capitalization is more than eight times Ceva's, though both remain unprofitable on a GAAP (Generally Accepted Accounting Principles) basis.
  • Contrasting momentum: MaxLinear shares have surged more than 400% over the past year, while Ceva has pulled back sharply after a strong 2026 run.
  • Different AI exposure: MaxLinear rides AI data-center optics; Ceva targets edge AI and connectivity licensing.
  • Valuation tension: Both trade on elevated multiples relative to current earnings, making sentiment and execution the key variables.

Why Compare These Two AI Plays

Ceva, Inc. and MaxLinear, Inc. often come up together in discussions about artificial-intelligence hardware because each offers a distinct route to the opportunity. They sit at opposite ends of the chip value chain: Ceva earns from design IP and royalties, while MaxLinear produces and sells finished integrated circuits. This comparison matters for investors considering a smaller, IP-focused edge AI and connectivity name against a larger, product-oriented business tied to data-center optical infrastructure. Looking at their performance, positioning, and recent drivers helps show which profile might fit better in today's market.

Ceva's Position and Recent Moves

Ceva supplies silicon and software IP for wireless connectivity, smart sensing, and AI processing, including its NeuPro neural processing unit architecture. Revenue comes mainly from licensing deals and royalties instead of direct chip sales, which supports an asset-light model and strong gross margins. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market action has been choppy for CEVA. The stock climbed earlier in 2026 before retreating in recent weeks, partly on profit-taking and questions about how fast design wins turn into steady royalties. The company posted a beat-and-raise quarter with revenue up roughly 13% year-over-year and announced a major AI licensing deal with a large software and AI platform company that chose its NeuPro-M NPU for custom silicon. It also grew its ultra-wideband partnership with LG Electronics. Even with these positives, shares sit well below the 52-week high, and analysts remain split between Buy and Hold ratings with a broad range of price targets.

MaxLinear's Momentum and Drivers

MaxLinear designs and sells radio-frequency, analog, and mixed-signal integrated circuits for broadband, connectivity, storage, and data-center uses. Its key growth area is optical interconnect silicon, specifically PAM4 digital signal processors for high-speed 400G and 800G links in hyperscale data centers.

MXL has been among the stronger semiconductor performers lately, with shares up more than 400% over the trailing 52 weeks. The June quarter showed revenue rising about 55% year-over-year and infrastructure revenue growing roughly 145%, making it the largest segment. MaxLinear also returned to GAAP profitability and raised its 2026 optical data-center outlook. The rally has pushed valuation into focus, with the stock at a premium to trailing sales and a notably high beta that highlights how sentiment can swing quickly.

Head-to-Head: Models, Growth, and Risks

The companies differ on several fronts. Ceva's licensing approach delivers high gross margins and low manufacturing needs, yet its revenue base stays modest and depends on turning design wins into royalties over time. MaxLinear's product model involves manufacturing costs and supply risks, but it has delivered stronger near-term revenue growth from optical infrastructure.

Ceva's growth centers on edge AI adoption, Wi-Fi and Bluetooth connectivity, and automotive sensing, while MaxLinear's depends on hyperscale spending for 800G links and future 1.6T platforms. Their AI exposure is complementary: one focuses on intelligent devices at the edge, the other on the infrastructure moving data between them.

Risks vary too. Ceva faces customer concentration and an unproven profitability track record, whereas MaxLinear contends with high valuation expectations, volatile share-price history, and exposure to data-center spending cycles. MaxLinear's recent momentum has been stronger, though Ceva's pullback has prompted some analyst upgrades on valuation.

Current AI Assessment

From what I see, the observable factors point toward favoring MXL right now. Its trend consistency, accelerating revenue, return to GAAP profitability, and raised optical outlook create a clearer momentum case than Ceva's, which is working through a sharp correction and limited evidence of lasting profitability. The view remains probabilistic, however. MaxLinear's steep valuation and high volatility leave it open to sentiment shifts, while Ceva's lower valuation and strategic AI licensing win could strengthen its position if conditions stabilize. The comparison comes down to a choice between established momentum and a more speculative turnaround narrative.

AI Tools for Timing Strategies

When evaluating entry and exit points in names like these, I sometimes turn to Tickeron's AI Trading Bots for additional perspective on automated approaches across different market conditions. The platform offers a range of strategies with varying timeframes and risk profiles, which can help align tactics with current trends without replacing core fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CEVA, MXL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CEVA in upward trend: price rose above 50-day moving average on September 21, 2026

CEVA moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 45 of 57 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 08, 2026. You may want to consider a long position or call options on CEVA as a result. In 71 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for CEVA just turned positive on September 02, 2026. Looking at past instances where CEVA's MACD turned positive, the stock continued to rise in 32 of 42 cases over the following month. The odds of a continued upward trend are 76%.

Following a +3.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where CEVA advanced for three days, in 211 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

CEVA broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CEVA entered a downward trend on September 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. CEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.851) is normal, around the industry mean (7.892). P/E Ratio (237.333) is within average values for comparable stocks, (159.553). Projected Growth (PEG Ratio) (2.461) is also within normal values, averaging (3.726). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (6.321) is also within normal values, averaging (44.558).

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CEVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Broadcom Inc. (NASDAQ:AVGO), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), QUALCOMM (NASDAQ:QCOM), Analog Devices (NASDAQ:ADI).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 215.16B. The market cap for tickers in the group ranges from 86.8K to 5.49T. NVDA holds the highest valuation in this group at 5.49T. The lowest valued company is STRB at 86.8K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 7%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was 66%. IMOS experienced the highest price growth at 27%, while MOBX experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -55%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 52
Price Growth Rating: 44
SMR Rating: 72
Profit Risk Rating: 73
Seasonality Score: -18 (-100 ... +100)
View a ticker or compare two or three
CEVA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in designing and licensing silicon intellectual property for the handsets, mobile broadband, portable and consumer electronics markets

Industry Semiconductors

Industry
Semiconductors
Address
15245 Shady Grove Road
Phone
+1 240 308-8328
Employees
424
Web
https://www.ceva-dsp.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.